Courtagen Inks Emerging Markets Deal with Alliance Global Group

Nov 15, 2012

|

NEW YORK (GenomeWeb News) – Courtagen Life Sciences today said that Alliance Global Group will distribute the firm's molecular diagnostic tests in certain emerging markets.

Dubai-based Alliance Global sells biomedical products in the Middle East, Africa, and Asia. It will have exclusive rights to distribute a number of Courtagen tests for genetically based disorders. Thus far, the Woburn, Mass.-based firm offers tests for mitochondrial disorders and a new panel for epilepsy and seizure. Courtagen also plans to develop tests for other neurological disorders.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Concerns About Bias in Policies

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Reprogrammable DNA

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Lack of Diversity

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

This Week in Science

In Science this week: whole-genome sequencing of single sperm cells, and more.

Featured White Papers

The Ultimate Guide to Mouse Clinical Trials

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

Menu